TY  - JOUR
AU  - Sopić, Miron
AU  - Stopa, Victoria
AU  - Devaux, Yvan
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5432
PB  - Oxford University Press on behalf of the European Society of Cardiology
T2  - European Heart Journal
T1  - Leveraging epitranscriptomics for cardiovascular disease theranostics
VL  - 45
IS  - 13
SP  - 1098
EP  - 1100
DO  - 10.1093/eurheartj/ehad852
ER  - 

@article{
author = "Sopić, Miron and Stopa, Victoria and Devaux, Yvan",
year = "2024",
publisher = "Oxford University Press on behalf of the European Society of Cardiology",
journal = "European Heart Journal",
title = "Leveraging epitranscriptomics for cardiovascular disease theranostics",
volume = "45",
number = "13",
pages = "1098-1100",
doi = "10.1093/eurheartj/ehad852"
}

Sopić, M., Stopa, V.,& Devaux, Y.. (2024). Leveraging epitranscriptomics for cardiovascular disease theranostics. in European Heart Journal
Oxford University Press on behalf of the European Society of Cardiology., 45(13), 1098-1100.
https://doi.org/10.1093/eurheartj/ehad852

Sopić M, Stopa V, Devaux Y. Leveraging epitranscriptomics for cardiovascular disease theranostics. in European Heart Journal. 2024;45(13):1098-1100.
doi:10.1093/eurheartj/ehad852 .

Sopić, Miron, Stopa, Victoria, Devaux, Yvan, "Leveraging epitranscriptomics for cardiovascular disease theranostics" in European Heart Journal, 45, no. 13 (2024):1098-1100,
https://doi.org/10.1093/eurheartj/ehad852 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Karaduzovic-Hadziabdic, Kanita
AU  - Kardassis, Dimitris
AU  - Maegdefessel, Lars
AU  - Martelli, Fabio
AU  - Meerson, Ari
AU  - Munjas, Jelena
AU  - Niculescu, Loredan S.
AU  - Stoll, Monika
AU  - Magni, Paolo
AU  - Devaux, Yvan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5616
AB  - Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.
PB  - Elsevier Ltd.
T2  - Journal of Molecular and Cellular Cardiology Plus
T1  - Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges
VL  - 6
SP  - 100048
DO  - 10.1016/j.jmccpl.2023.100048
ER  - 

@article{
author = "Sopić, Miron and Karaduzovic-Hadziabdic, Kanita and Kardassis, Dimitris and Maegdefessel, Lars and Martelli, Fabio and Meerson, Ari and Munjas, Jelena and Niculescu, Loredan S. and Stoll, Monika and Magni, Paolo and Devaux, Yvan",
year = "2023",
abstract = "Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.",
publisher = "Elsevier Ltd.",
journal = "Journal of Molecular and Cellular Cardiology Plus",
title = "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges",
volume = "6",
pages = "100048",
doi = "10.1016/j.jmccpl.2023.100048"
}

Sopić, M., Karaduzovic-Hadziabdic, K., Kardassis, D., Maegdefessel, L., Martelli, F., Meerson, A., Munjas, J., Niculescu, L. S., Stoll, M., Magni, P.,& Devaux, Y.. (2023). Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus
Elsevier Ltd.., 6, 100048.
https://doi.org/10.1016/j.jmccpl.2023.100048

Sopić M, Karaduzovic-Hadziabdic K, Kardassis D, Maegdefessel L, Martelli F, Meerson A, Munjas J, Niculescu LS, Stoll M, Magni P, Devaux Y. Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus. 2023;6:100048.
doi:10.1016/j.jmccpl.2023.100048 .

Sopić, Miron, Karaduzovic-Hadziabdic, Kanita, Kardassis, Dimitris, Maegdefessel, Lars, Martelli, Fabio, Meerson, Ari, Munjas, Jelena, Niculescu, Loredan S., Stoll, Monika, Magni, Paolo, Devaux, Yvan, "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges" in Journal of Molecular and Cellular Cardiology Plus, 6 (2023):100048,
https://doi.org/10.1016/j.jmccpl.2023.100048 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Vilne, Baiba
AU  - Gerdts, Eva
AU  - Trindade, Fábio
AU  - Uchida, Shizuka
AU  - Khatib, Soliman
AU  - Wettinger, Stephanie Bezzina
AU  - Devaux, Yvan
AU  - Magni, Paolo
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5145
AB  - Multiomics studies offer accurate preventive and therapeutic strategies for atherosclerotic cardiovascular disease (ASCVD) beyond traditional risk factors. By using artificial intelligence (AI) and machine learning (ML) approaches, it is possible to integrate multiple ‘omics and clinical data sets into tools that can be utilized for the development of personalized diagnostic and therapeutic approaches. However, currently multiple challenges in data quality, integration, and privacy still need to be addressed. In this opinion, we emphasize that joined efforts, exemplified by the AtheroNET COST Action, have a pivotal role in overcoming the challenges to advance multiomics approaches in ASCVD research, with the aim to foster more precise and effective patient care.
PB  - Elsevier Ltd
T2  - Trends in Molecular Medicine
T1  - Multiomics tools for improved atherosclerotic cardiovascular disease management
VL  - 29
IS  - 12
SP  - 983
EP  - 995
DO  - 10.1016/j.molmed.2023.09.004
ER  - 

@article{
author = "Sopić, Miron and Vilne, Baiba and Gerdts, Eva and Trindade, Fábio and Uchida, Shizuka and Khatib, Soliman and Wettinger, Stephanie Bezzina and Devaux, Yvan and Magni, Paolo",
year = "2023",
abstract = "Multiomics studies offer accurate preventive and therapeutic strategies for atherosclerotic cardiovascular disease (ASCVD) beyond traditional risk factors. By using artificial intelligence (AI) and machine learning (ML) approaches, it is possible to integrate multiple ‘omics and clinical data sets into tools that can be utilized for the development of personalized diagnostic and therapeutic approaches. However, currently multiple challenges in data quality, integration, and privacy still need to be addressed. In this opinion, we emphasize that joined efforts, exemplified by the AtheroNET COST Action, have a pivotal role in overcoming the challenges to advance multiomics approaches in ASCVD research, with the aim to foster more precise and effective patient care.",
publisher = "Elsevier Ltd",
journal = "Trends in Molecular Medicine",
title = "Multiomics tools for improved atherosclerotic cardiovascular disease management",
volume = "29",
number = "12",
pages = "983-995",
doi = "10.1016/j.molmed.2023.09.004"
}

Sopić, M., Vilne, B., Gerdts, E., Trindade, F., Uchida, S., Khatib, S., Wettinger, S. B., Devaux, Y.,& Magni, P.. (2023). Multiomics tools for improved atherosclerotic cardiovascular disease management. in Trends in Molecular Medicine
Elsevier Ltd., 29(12), 983-995.
https://doi.org/10.1016/j.molmed.2023.09.004

Sopić M, Vilne B, Gerdts E, Trindade F, Uchida S, Khatib S, Wettinger SB, Devaux Y, Magni P. Multiomics tools for improved atherosclerotic cardiovascular disease management. in Trends in Molecular Medicine. 2023;29(12):983-995.
doi:10.1016/j.molmed.2023.09.004 .

Sopić, Miron, Vilne, Baiba, Gerdts, Eva, Trindade, Fábio, Uchida, Shizuka, Khatib, Soliman, Wettinger, Stephanie Bezzina, Devaux, Yvan, Magni, Paolo, "Multiomics tools for improved atherosclerotic cardiovascular disease management" in Trends in Molecular Medicine, 29, no. 12 (2023):983-995,
https://doi.org/10.1016/j.molmed.2023.09.004 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Kararigas, Georgios
AU  - Devaux, Yvan
AU  - Magni, Paolo
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4916
PB  - Oxford University Press
T2  - European heart journal
T1  - Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research
VL  - 44
IS  - 24
SP  - 2143
EP  - 2145
DO  - 10.1093/eurheartj/ehad153
ER  - 

@article{
author = "Sopić, Miron and Kararigas, Georgios and Devaux, Yvan and Magni, Paolo",
year = "2023",
publisher = "Oxford University Press",
journal = "European heart journal",
title = "Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research",
volume = "44",
number = "24",
pages = "2143-2145",
doi = "10.1093/eurheartj/ehad153"
}

Sopić, M., Kararigas, G., Devaux, Y.,& Magni, P.. (2023). Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research. in European heart journal
Oxford University Press., 44(24), 2143-2145.
https://doi.org/10.1093/eurheartj/ehad153

Sopić M, Kararigas G, Devaux Y, Magni P. Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research. in European heart journal. 2023;44(24):2143-2145.
doi:10.1093/eurheartj/ehad153 .

Sopić, Miron, Kararigas, Georgios, Devaux, Yvan, Magni, Paolo, "Call for participation in the AtheroNET COST Action to implement multiomics in atherosclerotic cardiovascular disease research" in European heart journal, 44, no. 24 (2023):2143-2145,
https://doi.org/10.1093/eurheartj/ehad153 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Robinson, Emma L.
AU  - Emanueli, Costanza
AU  - Srivastava, Prashant
AU  - Angione, Claudio
AU  - Gaetano, Carlo
AU  - Condorelli, Gianluigi
AU  - Martelli, Fabio
AU  - Pedrazzini, Thierry
AU  - Devaux, Yvan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4746
AB  - The number of “omics” approaches is continuously growing. Among others, epigenetics has appeared as an attractive area of investigation by the cardiovascular research community, notably considering its association with disease development. Complex diseases such as cardiovascular diseases have to be tackled using methods integrating different omics levels, so called “multi-omics” approaches. These approaches combine and co-analyze different levels of disease regulation. In this review, we present and discuss the role of epigenetic mechanisms in regulating gene expression and provide an integrated view of how these mechanisms are interlinked and regulate the development of cardiac disease, with a particular attention to heart failure. We focus on DNA, histone, and RNA modifications, and discuss the current methods and tools used for data integration and analysis. Enhancing the knowledge of these regulatory mechanisms may lead to novel therapeutic approaches and biomarkers for precision healthcare and improved clinical outcomes.
PB  - Springer Science and Business Media Deutschland GmbH
T2  - Basic Research in Cardiology
T1  - Integration of epigenetic regulatory mechanisms in heart failure
VL  - 118
IS  - 1
DO  - 10.1007/s00395-023-00986-3
ER  - 

@article{
author = "Sopić, Miron and Robinson, Emma L. and Emanueli, Costanza and Srivastava, Prashant and Angione, Claudio and Gaetano, Carlo and Condorelli, Gianluigi and Martelli, Fabio and Pedrazzini, Thierry and Devaux, Yvan",
year = "2023",
abstract = "The number of “omics” approaches is continuously growing. Among others, epigenetics has appeared as an attractive area of investigation by the cardiovascular research community, notably considering its association with disease development. Complex diseases such as cardiovascular diseases have to be tackled using methods integrating different omics levels, so called “multi-omics” approaches. These approaches combine and co-analyze different levels of disease regulation. In this review, we present and discuss the role of epigenetic mechanisms in regulating gene expression and provide an integrated view of how these mechanisms are interlinked and regulate the development of cardiac disease, with a particular attention to heart failure. We focus on DNA, histone, and RNA modifications, and discuss the current methods and tools used for data integration and analysis. Enhancing the knowledge of these regulatory mechanisms may lead to novel therapeutic approaches and biomarkers for precision healthcare and improved clinical outcomes.",
publisher = "Springer Science and Business Media Deutschland GmbH",
journal = "Basic Research in Cardiology",
title = "Integration of epigenetic regulatory mechanisms in heart failure",
volume = "118",
number = "1",
doi = "10.1007/s00395-023-00986-3"
}

Sopić, M., Robinson, E. L., Emanueli, C., Srivastava, P., Angione, C., Gaetano, C., Condorelli, G., Martelli, F., Pedrazzini, T.,& Devaux, Y.. (2023). Integration of epigenetic regulatory mechanisms in heart failure. in Basic Research in Cardiology
Springer Science and Business Media Deutschland GmbH., 118(1).
https://doi.org/10.1007/s00395-023-00986-3

Sopić M, Robinson EL, Emanueli C, Srivastava P, Angione C, Gaetano C, Condorelli G, Martelli F, Pedrazzini T, Devaux Y. Integration of epigenetic regulatory mechanisms in heart failure. in Basic Research in Cardiology. 2023;118(1).
doi:10.1007/s00395-023-00986-3 .

Sopić, Miron, Robinson, Emma L., Emanueli, Costanza, Srivastava, Prashant, Angione, Claudio, Gaetano, Carlo, Condorelli, Gianluigi, Martelli, Fabio, Pedrazzini, Thierry, Devaux, Yvan, "Integration of epigenetic regulatory mechanisms in heart failure" in Basic Research in Cardiology, 118, no. 1 (2023),
https://doi.org/10.1007/s00395-023-00986-3 . .

TY  - JOUR
AU  - de Gonzalo-Calvo, David
AU  - Sopić, Miron
AU  - Devaux, Yvan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4362
AB  - In the past decade, significant resources have been invested in long noncoding RNA (lncRNA) research. Despite the knowledge available, we are far from incorporation of lncRNA into clinical practice. Here, we emphasize the technical challenges in the field, hoping to provoke a response leading to new consensus and guidelines.
PB  - Elsevier B.V.
T2  - Trends in Molecular Medicine
T1  - Methodological considerations for circulating long noncoding RNA quantification
VL  - 28
IS  - 8
SP  - 616
EP  - 618
DO  - 10.1016/j.molmed.2022.05.011
ER  - 

@article{
author = "de Gonzalo-Calvo, David and Sopić, Miron and Devaux, Yvan",
year = "2022",
abstract = "In the past decade, significant resources have been invested in long noncoding RNA (lncRNA) research. Despite the knowledge available, we are far from incorporation of lncRNA into clinical practice. Here, we emphasize the technical challenges in the field, hoping to provoke a response leading to new consensus and guidelines.",
publisher = "Elsevier B.V.",
journal = "Trends in Molecular Medicine",
title = "Methodological considerations for circulating long noncoding RNA quantification",
volume = "28",
number = "8",
pages = "616-618",
doi = "10.1016/j.molmed.2022.05.011"
}

de Gonzalo-Calvo, D., Sopić, M.,& Devaux, Y.. (2022). Methodological considerations for circulating long noncoding RNA quantification. in Trends in Molecular Medicine
Elsevier B.V.., 28(8), 616-618.
https://doi.org/10.1016/j.molmed.2022.05.011

de Gonzalo-Calvo D, Sopić M, Devaux Y. Methodological considerations for circulating long noncoding RNA quantification. in Trends in Molecular Medicine. 2022;28(8):616-618.
doi:10.1016/j.molmed.2022.05.011 .

de Gonzalo-Calvo, David, Sopić, Miron, Devaux, Yvan, "Methodological considerations for circulating long noncoding RNA quantification" in Trends in Molecular Medicine, 28, no. 8 (2022):616-618,
https://doi.org/10.1016/j.molmed.2022.05.011 . .